ESE. V. Shaposhnikova

E. V. Shaposhnikova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


E. V. Shaposhnikova has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Efficacy and safety of iron supplements in the treatment of anemia in pregnant women

    by E. V. Shaposhnikova, M. I. Bazina, D. D. Dolgih, N. A. Semenova, A. A. Shilovskaya

    Introduction. Therapy for iron deficiency conditions that complicate pregnancy, childbirth, and the postpartum period is always considered from the standpoint of the relationship between the safety and effectiveness of the medication, forming the patient’s commitment to long-term treatment. Aim. To analyze the therapeutic efficacy, clinical tolerance and perinatal outcomes when using a ferrous sulfate medication and Ascorbic acid in the treatment of iron deficiency anemia (IDA) in pregnant women. Materials and methods. The study included 61 women diagnosed with mild IDA in the first half of pregnancy (main group). The medication for treatment of Iron deficient anemia was used Sorbifer Durules (iron sulfate 100 mg Fe 2+ and Ascorbic acid 60 mg) 100 mg two times per day, until the normalization of hematological parameters and improvement of the clinical picture, with a transition to 100 mg per day until delivery to prevent IDA. The control group included 43 pregnant women without IDA. Results. The gestational age included in the observation was 14.9 (3.9) weeks. The positive dynamics were revealed an increase in hemoglobin levels by 6.3 g/l (p < 0.05) after one month of the therapy with further increase in hemoglobin at the end of the third trimester of pregnancy (36.9 ± 1.0 week) by 10.4 g/l (p < 0.05). A decrease in hemoglobin levels to 109.2 ± 6.5 and 114.1 ± 8.4 g/l was noted in patients of the main and control groups after delivery, while maintaining average parameters within the physiological values for the first week of the postpartum period (more than 100 g/l). Adverse events during treatment were recorded in 4.9% of pregnant women; there were no clinical cases requiring cessation of medication. Conclusion. Clinical data and hematological parameters during therapy with a combination of Ferrous sulfate and Ascorbic acid in an extended-release formula (Sorbifer Durules) in pregnant women demonstrated good tolerance and efficacy in the treatment of iron deficiency anemia.

  • Open Access

    Iron deficiencyanemia and pregnancy: Treatment options

    by E. V. Shaposhnikova, M. I. Bazina, D. D. Dolgih, N. A. Semenova, A. A. Shilovskaya

    Introduction . The choice of medications for the treatment of iron deficiency anemia (IDA) in a pregnant woman is based on therapeutic efficacy and safety, forming a high patient compliance to long-term therapy Aim . To evaluate the therapeutic efficacy, clinical tolerance and safety of using a medication based on iron sulfate and ascorbic acid in the treatment of iron deficiency anemia in pregnant women Materials and methods . The study included 155 women diagnosed with IDA: twenty-four pregnant women in the first trimester (group 1), forty-five pregnant women in the second trimester (group 2), and eighty-six patients in the third trimester (group 3). Antianemic therapy was administered to all pregnant women with Sorbifer Durules (iron sulfate 100 mg of iron sulfate and 60 mg of ascorbic acid) 100 mg two times per day for a long time until normalization of hematological parameters and improvement of the clinical symptoms with a transition to 100 mg per day until delivery for the purpose of preventing IDA. Results. The gestational age included in the observation were 10.6 (1.6), 20.2 (2.6) and 30.9 (2.6) weeks. When analyzing hematological parameters changes in 1 month after the start of therapy, there was positive dynamic which revealed the increase in hemoglobin levels by 5.4 g/l and 7.2 g/l in patients of groups 1 and 2, respectively (p < 0.05), with a continuing tendency to increase at 37.1 ± 1.1 weeks by 10.3 g/l and 9.7 g/l (p < 0.05). It was noted that there was a decrease in the number of patients with IDA in group 1to 20.8%, which is 1.5 and 2.1 times lower compared to groups 2 and 3 (p = 0.03). Adverse reactions when taking Sorbifer Durules were registered in 3.2% of pregnant women, there were no clinical situations requiring discontinuation of the medication. Conclusion. The combination of iron sulfate and ascorbic acid in a prolonged release formula (Sorbifer Durules) is a well-tolerated and effective treatment option of IDA at any stage of pregnancy.

  • Open Access

    Iron deficiency in women during pregnancy

    by E. V. Shaposhnikova, M. I. Bazina, D. D. Dolgih

    Introduction. In the context of iron deficiency states in women of reproductive age and, as a result during pregnancy, leads to the formation of the gestational complications and negatively perinatal outcomes. The routine screening for the detection of iron deficiency by determining the level of ferritin allows you to formed risk groups in order to carry out timely correction.Aim. To estimate the level and rate of an iron deficiency state in pregnant women in the first trimester.Materials and methods. The study included 401 pregnant women under surveillance in the period from January to June 2023. The main group was 134 patients with a diagnosis of iron deficiency – 33.4% of the total number of examined. The comparison group is represented by 36 pregnant women with the level of serum ferritin 41 – 60 ug/l.Results. The mean age and gestation of patients in the main and control groups were 27.9 (6.1) and 28.7 (6.8) years and 10.7 (1.9) and 10.6 (1.8) weeks, respectively. The serum ferritin level was 20.57 ± 8.83 ug/l in the patients of the main group and was significantly lower compared to the control group 49.74 ± 6.96 ug/l (p = 0.01). Among the patients in the main group, more than 80% had severe absolute iron deficiency (SF concentration < 15 ug/l), detected in 29.1% of women (39/134) and absolute iron deficiency (SF concentration ≥ 15 – < 30 ug/l) – 52.9% of cases (71/134). Features of the observation showed that in the 2nd trimester of pregnancy in patients with iron deficiency, the diagnosis of anemia was detected 2.6 times more often – 31.3% (42/134) compared to the control group.Conclusions. Determination of serum ferritin allows to identify patients with iron deficiency and timely prescribe iron preparations in preventive/therapeutic doses to reduce the frequency of perinatal and maternal complications.


  • Treatment of nonspecific vulvovaginitis in pregnant women: evaluation of the effectiveness of two-stage therapy

    by E.V. Shaposhnikova, E.SH. Majidli

    Purpose of the study. To evaluate the clinical and laboratory effectiveness and long-term results of the two-stage therapy for nonspecific vulvovaginitis in pregnant women in the third trimester using the antiseptic dequalinium chloride (Fluomizin) and the probiotic (Gynoflor E). Material and methods. There were sixty-nine pregnant women in the third trimester of gestation observed in the outpatient setting. The treatment was carried out in two sequent stages. Patients of the main and the control groups (n=69) received local treatment with an antiseptic: dequalinium chloride (Fluomizin) containing 10 mg in a vaginal tablet for six days, one tablet intravaginally per day in the first stage. Topical probiotics were used to restore the vaginal normocenosis state in the second stage. Patients in the main group (n=36) used a drug containing L. acidophilus lyophilisate 50.00 mg (at least 108 viable bacteria) and an ultra-low dose of estriol — 0.03 mg (Gynoflor E) for six days, one tablet intravaginally per day. Patients in the control group (n=33) received a course of treatment using intravaginal capsules containing a lyophilized culture of lactobacilli L. casei rhamnosus Doderleini (at least 108 CFU), one capsule twice per day for seven days. Evaluation of the effectiveness of the therapy included primary results such as dynamics of complaints, findings on vaginal speculum examination and microscopic examination of vaginal smears. Secondary results of the assessment included the overall duration and dynamics of the labor (vaginal or surgical intervention), birth trauma (rupture of the cervix or vagina), the development of signs of chorioamnionitis and intra-amniotic infection of the fetus, the condition of newborns and the postpartum period. Results. The improvement in the condition was noted such as a relief of clinical manifestations in 97.2% (35/36) (p<0.05) of patients in the main group and in 93.9% (31/33) (p<0.05) of patients control group in the absence of statistical significance of differences between groups (p = 0.51) during the threatment. Microscopy assessment showed that laboratory cure included in the normalization of leukocyte number in 94.4% (34/36, p<0.05) of patients in the main group and in 93.9% (31/33, p<0.05) control groups. The use of the complex two-stage therapy: an antiseptic (Fluomizin) and a probiotic with a microdose of estriol (Ginoflor E), contributed to a decrease in the concentration of small gram-variable cocci towards the predominance of single (1—10 per p/z) and moderate amounts (11—100 p/z) microorganisms with a simultaneous increase in the content of lactobacilli and their prevalence (moderate and large numbers) over other microflora in 91.7% (33/36) compared to the initial data (p<0.05). Conclusion. The data showed the high effectiveness of the complex two-stage therapy by using the antiseptic dequalinium chloride and the probiotic Ginoflor E in the treatment of nonspecific vulvovaginitis in pregnant women in the third trimester with the frequency of achieving a general therapeutic effect in 95.8% of patients (p<0.05), the absence of serious adverse events and the high satisfaction from using the drug in 97.2% of pregnant women.

  • A personalized approach in the pregnancy management and the method of delivery in patients with impaired carbohydrate metabolism

    by E.V. Shaposhnikova, D.A. Maiseenko, Y.E. Semenova, K.I. Mentsik

    Background. Patients with impaired carbohydrate metabolism are at risk of developing diabetic fetopathy, premature birth and surgical delivery. Strict follow-up to the relevant clinical guidelines for the diagnosis of carbohydrate metabolism disorders, pregnancy management, the choice of the planned date and method of delivery are aimed at reducing the risk of obstetric and perinatal complications. Objective. To analyse perinatal outcomes, duration and method of delivery in patients with impaired carbohydrate metabolism over the past 5 years (2018, 2022). Materials and methods. The birth charts of 885 patients with carbohydrate metabolism disorders who were hospitalised prenatally and delivered in the maternity hospital were analysed. Results. The number of patients with carbohydrate metabolism disorders increased 2.3 times over the past 5 years, from 13,6% (315/2320) in 2018 to 30,9% (570/1840) in 2022 (RR = 0,58; 95% CI 0,53-0,64; p < 0,001), due to patients with GDM, the number of births increased by 2,5 times in relation to the total number of deliveries, from 11,7% (271/2320) in 2018 to 29,3% (540/1840) in 2022 (RR = 0,55; 95% CI 0,49-0,60; p < 0.001). Structure analysis of gestational complications showed that the incidence of diabetic fetopathy is 2,4 times less often: 7,9% (45/570) in 2022 vs 19,4% in 2018 (61/315) (RR = 1,77; 95% CI 1,46-2,14; р < 0,001), a decrease in moderate preeclampsia by 2,3 times is determined. Reduction in the frequency of perinatal complications allows you to prolong pregnancy to full term. The number of preterm births decreased by 5%, from 6,4% (20/315) in 2018 to 1,4% (8/570) in 2020 (RR = 2.07; 95% CI 1,61-2,67; р < 0,05). The number of planned births increased by 18,6%, from 25,1% (79/315) in 2018 to 43,7% (249/570) in 2022 (RR = 0.57; 95% CI 0,46-0,70; р < 0,001). It reduced the percentage of caesarean sections by a factor of 3,2, from 46,9% (148/315) in 2018 to 14,7% (84/570) in 2022(RR = 2,49; 95% CI 2,12-2,94; р< 0,001). Conclusion. Timely diagnosis of carbohydrate metabolism disorders and correctly chosen management tactics are foundation for likelihood vaginal delivery at full term.